RapidAI has received U.S. Food and Drug Administration (FDA) clearance for Aortic Management, part of its Rapid Aortic AI-based software for assessment and management of aortic disease.
Built on the Rapid Enterprise Platform, Rapid Aortic is designed to assist clinicians in quickly and accurately identifying aortic aneurysms, dissections, and other anomalies, according to the San Mateo, CA-based company.
Rapid Aortic is integrated into RapidAI's Rapid Edge Cloud, and all of its modules are integrated into its Rapid Navigator Pro and Rapid mobile and web applications to work together across PACS, EHR, and reporting systems.
The software is designed to enable analysis of all CT scans that include the aorta, including post-treatment and non-contrast studies, and to assist in identifying and tracking pathology, RapidAI added.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
